Equities Analysts Set Expectations for PCRX FY2027 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – Analysts at Zacks Research issued their FY2027 EPS estimates for Pacira BioSciences in a research note issued to investors on Thursday, March 20th. Zacks Research analyst R. Department anticipates that the company will post earnings of $2.45 per share for the year. The consensus estimate for Pacira BioSciences’ current full-year earnings is $2.41 per share.

A number of other research analysts have also weighed in on PCRX. Barclays raised their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Royal Bank of Canada restated a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright boosted their price objective on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Needham & Company LLC raised their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Trading Down 1.2 %

PCRX stock opened at $24.54 on Monday. Pacira BioSciences has a 12-month low of $11.16 and a 12-month high of $31.67. The business’s 50-day moving average is $24.60 and its 200 day moving average is $19.76. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -12.09 and a beta of 0.86.

Institutional Investors Weigh In On Pacira BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in Pacira BioSciences by 269.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock valued at $5,955,000 after purchasing an additional 288,662 shares during the last quarter. Verition Fund Management LLC purchased a new position in shares of Pacira BioSciences during the third quarter worth $493,000. Segall Bryant & Hamill LLC acquired a new stake in shares of Pacira BioSciences in the third quarter valued at $483,000. Centiva Capital LP purchased a new stake in shares of Pacira BioSciences in the 3rd quarter valued at $398,000. Finally, State Street Corp raised its holdings in shares of Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after buying an additional 110,162 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.